Remix Therapeutics Collaborates with Janssen to Advance Small Molecule Therapeutics
Janssen will pay upwards of $1 billion for exclusive rights to use Remix’s RNA-based drug discovery platform on three specific targets.
Remix Therapeutics, a biotechnology company focusing on reprogramming RNA processing, announced a strategic collaboration with Janssen Pharmaceutica NV on Feb. 17, 2022. The strategic partnership will see Janssen use Remix’s REMaster drug discovery platform for the discovery and development of small molecule therapeutics that modulate RNA processing.
Per the terms of the agreement, Janssen will have exclusive rights to three specific targets with applications in oncology and immunology. In exchange, Remix will receive an initial payment of $45 million, but could receive over $1 billion in payments should it meet regulatory approvals and various other conditions.
“We look forward to collaborating with this innovative team,” said Peter Smith, co-founder and CEO of Remix Therapeutics, in a company press release. “Janssen is an ideal strategic partner for our REMaster platform. This collaboration further validates the therapeutic potential of our proprietary REMaster drug discovery platform and provides additional resources to translate our cutting-edge science into new medicines.”
Source: Remix Therapeutics
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
